The revised Annex 1, “Manufacture of Sterile Medicinal Products”, was published by the European Commission in August 2022 and came into effect in August 2023, with one provision on lyophiliser loading deferred to August 2024. PIC/S adopted the same text, so it applies well beyond the EU — including the UK and the many authorities that follow the PIC/S guide.
Annex 1 requires sterile manufacturers to implement a contamination control strategy across the facility to define all critical control points and assess the effectiveness of all the controls — design, procedural, technical and organisational — and the monitoring measures used to manage risks to medicinal product quality and safety. The strategy is expected to be based on quality risk management and to be actively updated as knowledge improves.
Annex 1 also lists the elements a CCS should consider. They range from plant and process design, premises, equipment, personnel and utilities through raw materials, containers and closures, supplier approval and outsourced services, to process risk assessment, validation, sterilisation, preventive maintenance, cleaning and disinfection, monitoring systems, prevention mechanisms such as trending, investigation and CAPA, and continuous improvement.
Although Annex 1 is written for sterile products, its principles — including a contamination control strategy — are increasingly applied to non-sterile manufacturing too.